(Q33361458)

English

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). (English)

1 reference

Europe PubMed Central

26 July 2017

phase I clinical trial

0 references

multicenter clinical trial

0 references

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Michael Koenigsmann

1

1 reference

Europe PubMed Central

26 July 2017

Wolfgang Knauf

2

1 reference

Europe PubMed Central

26 July 2017

Michael Herold

3

1 reference

Europe PubMed Central

26 July 2017

Rita Pasold

4

1 reference

Europe PubMed Central

26 July 2017

Gerd Müller

5

1 reference

Europe PubMed Central

26 July 2017

Henning Eschenburg

6

1 reference

Europe PubMed Central

26 July 2017

Christoph Kahl

7

1 reference

Europe PubMed Central

26 July 2017

Volker Lakner

8

1 reference

Europe PubMed Central

26 July 2017

Michael Assmann

9

1 reference

Europe PubMed Central

26 July 2017

Kathleen Jentsch-Ullrich

10

1 reference

Europe PubMed Central

26 July 2017

Martin Mohren

11

1 reference

Europe PubMed Central

26 July 2017

Rainer Bartsch

12

1 reference

Europe PubMed Central

26 July 2017

Astrid Franke

13

1 reference

Europe PubMed Central

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 2004

1 reference

Europe PubMed Central

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

26 July 2017

45

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

1821-1827

1 reference

Europe PubMed Central

26 July 2017

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Metabolism and mechanisms of action of bendamustine: rationales for combination therapies

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

A systematic review of the role of pulmonary irradiation in the management of primary bone tumours

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

[Therapeutic results and toxic side effects of the cytostasan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer].

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1080%2F1042819042000223822

21 January 2018

Identifiers

10.1080/1042819042000223822

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33361458&oldid=1971987632"